The FDA's Critique of the Anturane Reinfarction Trial

New England Journal of Medicine

Volumn 303, Issue 25, 1980, Pages 1488-1492

  Temple, Robert ^a   Pledger, Gordon W ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SULFINPYRAZONE;

ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; METHODOLOGY; MORTALITY; RANDOMIZATION; SUDDEN DEATH; UNITED STATES;

CLINICAL TRIALS; DEATH, SUDDEN; DOUBLE-BLIND METHOD; HUMANS; MYOCARDIAL INFARCTION; PLACEBOS; RANDOM ALLOCATION; RESEARCH DESIGN; SULFINPYRAZONE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0019328346     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198012183032534     Document Type: Article

References (4)

1. The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med. 1980; 302:250-256.
2. The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: the Anturane Reinfarction Trial. N Engl J Med. 1978; 298:289-295.
3. Relman A.S. New job for an old drug? N Engl J Med. 1978; 298:333-334.
4. Braunwald E. Treatment of the patient after myocardial infarction: the last decade and the next. N Engl J Med. 1980; 302:290-293.